Inhallation of e-Cigarette Cartridge Solution Aggravates Allergen-induced Airway Inflammation and Hyper-responsiveness in Mice

Heung Bin Lim, Seung Hyung Kim, Heung Bin Lim, Seung Hyung Kim

Abstract

Electronic cigarettes (e-cigarettes) are becoming increasingly popular worldwide and their cellular effects warrant further evaluation. In this study, we investigated the effects of an e-cigarette cartridge solution on allergen related asthmatic airway inflammation (AI) and airway hyperresponsiveness (AHR), when it is delivered by intratracheal route in mice. Asthmatic AI and AHR were induced by systemic sensitization to ovalbumin (OVA) followed by intratracheal, intraperitoneal, and aerosol allergen challenges in BALB/c mice. The cartridge solution of e-cigarette (containing 16 mg/ml nicotine) was diluted 50 times and 100 μl of the diluted solution was intratracheally instilled to OVA-sensitized (OVA-S) mice two times a week for 10 weeks. Long-term e-cigarette inhalation elicited no remarkable changes in the activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase enzymes in serum, however, increased infiltration of inflammatory cells including eosinophils, into airways from blood, aggravated the asthmatic AI and AHR, and stimulated the production of cytokines such as interleukin (IL)-4, IL-5 and IL-13, and OVA-specific IgE production. Our data suggest that the inhalation of e-cigarette solutions can function as an important factor to exacerbate the allergy-induced asthma symptoms. Further studies are needed to address the effects of e-cigarette solutions on human health.

Keywords: Airway hyperresponsiveness; Airway inflammation; Cytokine; Electronic cigarettes; Eosinophils; IgE.

Figures

Fig. 1.. Effects of e-cigarettes on airway…
Fig. 1.. Effects of e-cigarettes on airway hyper-responsiveness. N, normal group; OVA-S, OVA-sensitized group; OVA-S + E-C, group sensitized with OVA and instilled with nicotine solution from e-cigarettes; Penh, enhanced pause value in asthma assessment; MCH, methacholine. *p< 0.01 compared to the N group and #p < 0.05 compared to the OVA-S group, as assessed by, respectively.

References

    1. Uryupin A.B., Peregudov A.S., Kochetkov K.A., Bulatnikova L.N., Kiselev S.S., Nekrasov Y.S. Qualitative and quantitative compositions of fluids for electronic cigarettes. Pharm. Chem. J. (2013);46:687–692. doi: 10.1007/s11094-013-0871-z.
    1. Polosa R., Caponnetto P., Morjaria J.B., Papale G., Campagna D., Russo C. Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health. (2011);11:786. doi: 10.1186/1471-2458-11-786.
    1. Ingebrathsen B.J., Cole S.K., Alderman S.L. Electronic cigarette aerosol particle size distribution measurements. Inhalation Toxicol. 2012;24:976–984. doi: 10.3109/08958378.2012.744781.
    1. Kuschner W.G., Reddy S., Mehrotra N., Paintal H.S. Electronic cigarettes and thirdhand tobacco smoke: two emerging health care challenges for the primary care provider. Int. J. Gen. Med. (2011);4:115–120. doi: 10.2147/IJGM.S16908.
    1. Lee S., Kimm H., Yun J.E., Jee S.H. Public health challenges of electric cigarettes in South Korea. J. Prev. Med. Public Health. (2011);44:235–241. doi: 10.3961/jpmph.2011.44.6.235.
    1. Laugesen M. Safety report on the Ruyan e-cigarette cartridge and inhaled aerosol, Health New Zealand Ltd. New Zealand; (2008). pp. 1–23.
    1. Food and Drug Administration. Summary of Results: Laboratory Analysis of Electronic Cigarettes Conducted By FDA. FDA; US: (2010). p. 1.
    1. Etter J.F. Electronic cigarettes: a survey of users. BMC Public Health. (2010);10:231. doi: 10.1186/1471-2458-10-231.
    1. Caponnetto P., Auditore R., Russo C., Cappello G.C., Polosa R. Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: A prospective 12-month pilot study. Int. J. Environ. Res. Public Health. (2013);10:446–461. doi: 10.3390/ijerph10020446.
    1. Flouris A.D., Chorti M.S., Poulianiti K.P., Jamurtas A.Z., Kostikas K., Tzatzarakis M.N., Wallace Hayes A., Tsatsakis A.M., Koutedakis T. Acute impact of active and passive electronic cigarette smoking on serum cotinin and lung function. Inhalation Toxicol. 3;25:91–101. doi: 10.3109/08958378.2012.758197.
    1. Siegel M.B., Tanwar K.L., Wood K.S. Electronic cigarettes as a smoking-cessation tool. Results from an online survey. Am. J. Prev. Med. (2011);40:472–475. doi: 10.1016/j.amepre.2010.12.006.
    1. Etter J.F., Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. (2011);106:2017–2028. doi: 10.1111/j.1360-0443.2011.03505.x.
    1. Vansickel A.R., Cobb C.O., Weaver M.F., Eissenberg T.E. A clinical laboratory model for evaluating the acute effects of electronic ‘'cigarettes’': nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol. Biomarkers Prev. (2010);19:1945–1953. doi: 10.1158/1055-9965.EPI-10-0288.
    1. Bullen C., McRobbie H., Thornley S., Glover M., Lin R., Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob. Control. (2010);19:98–103. doi: 10.1136/tc.2009.031567.
    1. Kim D.S., Kim S.H., Kim B.K., Yang M.C., Ma J.Y. Antiasthmatic effects of herbal complex MA and its fermented product MA128. Evid. Based Complement. Altern. Med. (2012);2012:769508.
    1. Kim S.H., Kim B.K., Lee Y.C. Antiasthmatic effects of hesperidin, a potential Th2 cytokine antagonist, in a mouse model of allergic asthma. Mediators Inflammation. (2011);2011:485402. doi: 10.1155/2011/485402.
    1. Cieslewicz G., Tomkinson A., Adler A., Duez C., Schwarze J., Takeda K., Larson K.A., Lee J.J., Irvin C.G., Gelfand E.W. The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. J. Clin. Invest. 9;104:301–308. doi: 10.1172/JCI7010.
    1. Lee Y.C., Kim S.H., Seo Y.B., Roh S.S., Lee J.C. Inhibitory effects of Actinidia polygama extract and cyclosporine A on OVA-induced eosinophilia and bronchial hyperresponsiveness in a murine model of asthma. Int. Immunopharmacol. (2006);6:703–713. doi: 10.1016/j.intimp.2005.10.007.
    1. Barnes P.J. Pathophysiology of allergic inflammation. Immunol. Rev. (2011);242:31–50. doi: 10.1111/j.1600-065X.2011.01020.x.
    1. Barlow R.B., McLeod L.J. Some studies on cytosine and its methylated derivatives. Br. J. Pharmacol. (1969);35:161–174. doi: 10.1111/j.1476-5381.1969.tb07977.x.
    1. Tomkinson A., Duez C., Cieslewicz G., Pratt J.C., Joetham A., Shanafelt M.C., Gundel R., Gelfand E.W. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13- induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J. Immunol. (2001);166:5792–5800.
    1. Bates J.H., Maksym G.N. Mechanical determinants of airways. (2011).
    1. Cockcroft D.W. Direct challenge tests: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. (2010);138:18S–24S. doi: 10.1378/chest.10-0088.
    1. Nakagome K., Nagata M. Pathogenesis of airway inflammation in bronchial asthma. Auris Nasus Larynx. (2011);38:555–563. doi: 10.1016/j.anl.2011.01.011.
    1. Brightling C.E. Eosinophils, bronchitis and asthma; Pathogenesis of cough and air flow obstruction. Pulm. Pharmacol. Ther. (2011);24:324–327. doi: 10.1016/j.pupt.2010.11.001.
    1. Amin K. The role of mast cells in allergic inflammation. Respir. Med. (2012);106:9–14. doi: 10.1016/j.rmed.2011.09.007.
    1. Bosnjak B., Stelzmueller B., Erb K.J., Epstein M.M. Treatment of allergic asthma: Modulation of Th2 cells and their responses. Respir. Res. (2011);12:114.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever